Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization

Related Experiment Video

Updated: Oct 6, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

G Lammering1, T H Hewit, W T Hawkins

  • 1Department of Radiation Oncology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.

Journal of the National Cancer Institute
|June 21, 2001
PubMed
Abstract

Insights

Gene therapy using EGFR-CD533 in tumors significantly increased radiosensitivity by inhibiting epidermal growth factor receptor (EGFR) activation. This approach shows promise for enhancing cancer treatment efficacy with ionizing radiation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Ionizing radiation activates epidermal growth factor receptor (EGFR) in cancer cells, promoting survival and reducing radiosensitivity.
  • A dominant-negative EGFR mutant (EGFR-CD533) can disrupt this protective response by blocking EGFR activation.

Purpose of the Study:

  • To investigate the potential of gene therapy using EGFR-CD533 to enhance tumor radiosensitivity.
  • To evaluate the effect of Ad-EGFR-CD533 gene transfer on tumor response to ionizing radiation in vivo.

Main Methods:

  • Human mammary carcinoma MDA-MB-231 xenograft tumors in nude mice were transduced with Ad-EGFR-CD533 or a control Ad-LacZ vector.
  • Tumors were exposed to therapeutic doses of ionizing radiation.
  • EGFR activation, radiosensitization, and tumor response were assessed.

Main Results:

  • Ad-EGFR-CD533 transduction reduced radiation-induced EGFR activation by 2.94-fold.
  • Transduced tumors exhibited significantly higher radiosensitivity (46% increase; P<.001).
  • A dose-enhancement ratio of 1.85 was observed, indicating increased efficacy of radiation therapy.

Conclusions:

  • Overexpression of EGFR-CD533 via adenoviral vector confers a dominant-negative EGFR phenotype.
  • This approach successfully induced tumor radiosensitization in xenograft models.
  • Disrupting EGFR function with EGFR-CD533 holds promise as a gene therapy to improve cancer treatment outcomes.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...